TDACW
Translational Development Acquisition Corp.
Key Financials
Operating Income
$-944538
↓ 381.0%
Net Income
$6.4M
↑ 9059.7%
Total Assets
$181.7M
↑ 3.8%
Cash & Equivalents
$29787.00
↓ 93.2%
Shareholders' Equity
$-6542108.00
↓ 16.9%
Total Liabilities
$6.6M
↑ 5.3%
Operating Cash Flow
$-608387.00
↑ 28.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/30/2026 | View on SEC |
| 10-Q | 11/14/2025 | View on SEC |
| SCHEDULE 13G/A | 10/10/2025 | View on SEC |
| 8-K | 8/14/2025 | View on SEC |
| 10-Q | 8/14/2025 | View on SEC |
| SCHEDULE 13G/A | 7/31/2025 | View on SEC |
| SCHEDULE 13G/A | 7/11/2025 | View on SEC |
| 10-Q | 5/15/2025 | View on SEC |
| SCHEDULE 13G/A | 5/14/2025 | View on SEC |
| SCHEDULE 13G/A | 5/14/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TDACW |
| Company Name | Translational Development Acquisition Corp. |
| CIK | 1926599 |
| Sector | Blank Checks |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 6770 |
| SIC Description | Blank Checks |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (413) 204-2769 |